MDxHealth Receives CLIA Certification and California State License for its Clinical Laboratory
Through its CLIA-certified laboratory, MDxHealth will commercialize proprietary epigenetic diagnostic service products for a number of cancer indications. The company expects to launch its first assay, Prostate ConfirmMDx™, in the first half of 2012.
“Having our CLIA laboratory operational marks the beginning of our commercial activities in the US, a key driver to our long-term success. The demand for molecular testing in cancer is growing rapidly. MDxHealth is now well-positioned to introduce its patented epigenetic tests which will aid physicians in the diagnosis and personalized treatment of their patients,” said Dr. Jan Groen, CEO of MDxHealth. “We have completed the laboratory construction and passed the state inspection in record time, demonstrating the dedication and proficiency of our operations team in Irvine. MDxHealth is building a world class scientific and commercial team in the US and plans further expansion in the months ahead.”
Most read news
Organizations
Other news from the department politics & laws
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.